Article
Hematology
Kaito Harada, Shohei Mizuno, Shingo Yano, Akiyoshi Takami, Hiroto Ishii, Kazuhiro Ikegame, Yuho Najima, Shinichi Kako, Takashi Ashida, Souichi Shiratori, Shuichi Ota, Makoto Onizuka, Kentaro Fukushima, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, Masamitsu Yanada
Summary: Although haploidentical donor lymphocyte infusion (DLI) is a valid treatment option for relapsed acute myeloid leukemia (AML), the incidence and risk factors for graft-versus-host disease (GVHD) and the efficacy of haploidentical DLI have not been fully evaluated. Our retrospective analysis showed that a higher CD3(+) cell count was associated with an increased risk of acute GVHD, and preemptive DLI resulted in better overall response.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Katrin Teich, Michael Stadler, Razif Gabdoulline, Jyoti Kandarp, Clara Wienecke, Bennet Heida, Piroska Klement, Konstantin Buttner, Letizia Venturini, Martin Wichmann, Wolfram Puppe, Christian Schultze-Florey, Christian Koenecke, Gernot Beutel, Matthias Eder, Arnold Ganser, Michael Heuser, Felicitas Thol
Summary: Donor lymphocyte infusions (DLIs) can be used to prevent or treat relapse in acute myeloid leukemia (AML) patients after allogeneic hematopoietic cell transplantation (alloHCT). Measurable residual disease (MRD) is a valuable biomarker for predicting the response and outcome of DLI treatment. This retrospective study showed that MRD status before and after DLI treatment is prognostic for event-free survival, overall survival, cumulative incidence of relapse, and relapse-free survival.
Article
Oncology
Raynier Devillier, Boris Calmels, Sophie Guia, Mohammed Taha, Cyril Fauriat, Bechara Mfarrej, Geoffroy Venton, Eric Vivier, Daniel Olive, Christian Chabannon, Didier Blaise, Sophie Ugolini
Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective curative option for high-risk hematologic malignancies, but disease recurrence remains a critical issue. NK cell-based immunotherapies offer a promising approach to enhance anti-tumor effects without triggering graft-versus-host disease. This clinical trial demonstrates the safety and potential efficacy of prophylactic donor-derived IL-2 activated NK cell infusion after allo-HSCT for patients with hematologic malignancies.
Article
Oncology
Elena Kum, Gabriele Jagelaviciute, Edward Li, Kenneth Williams, Santhosh Thyagu, Warren Fingrut
Summary: The article tells the story of a Canadian stem cell recipient who underwent transplantation from a matched unrelated donor for refractory chronic myelogenous leukemia, showcasing different perspectives and encouraging people to become donors.
Article
Immunology
Maite Alvarez, Antonio Pierini, Federico Simonetta, Jeanette Baker, Kristina Maas-Bauer, Toshihito Hirai, Robert S. Negrin
Summary: Allogeneic hematopoietic cell transplantation is an effective treatment option for hematological malignancies, but often results in severe toxicities. Less aggressive alternatives like NMAC and RIC have limitations including increased cancer relapse and limited persistence of donor chimerism. Strategies for accelerated and more durable donor engraftment are still needed.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Eva A. S. Koster, Edouard F. Bonneville, Peter A. von dem Borne, Peter van Balen, Erik W. A. Marijt, Jennifer M. L. Tjon, Tjeerd J. F. Snijders, Danielle van Lammeren, Hendrik Veelken, Hein Putter, J. H. Frederik Falkenburg, Constantijn J. M. Halkes, Liesbeth C. de Wreede
Summary: Alloreactive donor-derived T-cells play a crucial role in alloimmune responses after allogeneic hematopoietic stem cell transplantation (alloSCT), affecting both the prevention of leukemia relapse and the risk of graft-versus-host disease (GvHD). This study investigates the complex associations between T-cell kinetics and alloimmune responses in acute leukemia patients receiving alemtuzumab-based T-cell depletion alloSCT. The results demonstrate that donor lymphocyte infusion (DLI) can lead to detectable T-cell expansion, with CD4+ T-cells showing the strongest association with the development of alloimmune responses.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Anna Soderstrom, Sofie Vonlanthen, Kerstin Jonsson-Videsater, Stephan Mielke, Hannes Lindahl, Johan Torlen, Michael Uhlin
Summary: This study found that measuring TREC levels can predict the prognosis of adult AML patients after bone marrow transplantation, especially overall survival. Lower TREC levels were associated with viral infections and CMV reactivation. KREC levels were not associated with clinical outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Jintao Xia, Xuejie Li, Genyong Gui, Jian Wu, Shengnan Gong, Yuxin Shang, Jun Fan
Summary: This study evaluated the early immune response of recipients with disparate HCMV outcomes and found that HCMV-specific IFN-gamma secreting cells, HCMV IgG, and absolute lymphocyte count could represent the humoral and cellular immune response. Early monitoring of these immune markers could enable prediction of HCMV outcomes posttransplant and assessment of the severity of HCMV DNAemia.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Review
Cell & Tissue Engineering
Teng Li, Chengxin Luo, Jiasi Zhang, Ling Wei, Wei Sun, Qin Xie, Yan Liu, Yongli Zhao, Shuangnian Xu, Lihua Wang
Summary: The co-infusion of mesenchymal stem cells (MSCs) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) has shown improvement in engraftment and reduced risk of chronic graft-versus-host disease (cGVHD). However, the effects varied among different age and disease groups, suggesting potential benefits for certain populations.
STEM CELL RESEARCH & THERAPY
(2021)
Article
Hematology
Boris van der Zouwen, E. A. S. Koster, P. A. von dem Borne, L. E. M. Oosten, M. W. I. Roza-Scholten, T. J. F. Snijders, D. van Lammeren, P. van Balen, W. A. F. Marijt, H. Veelken, J. H. F. Falkenburg, L. C. de Wreede, C. J. M. Halkes
Summary: Prophylactic donor lymphocyte infusion (DLI) can introduce graft-versus-leukemia (GvL) effects with low risk of severe graft-versus-host-disease (GvHD) when initiated at 6 months after T cell-depleted allogeneic stem cell transplantation (TCD-alloSCT). This study retrospectively analyzed the use of low-dose early DLI at 3 months after alloSCT to prevent early relapse.
ANNALS OF HEMATOLOGY
(2023)
Review
Immunology
Adele Dhuyser, Alice Aarnink, Michael Peres, Jyothi Jayaraman, Neda Nemat-Gorgani, Marie Therese Rubio, John Trowsdale, James Traherne
Summary: Allogeneic hematopoietic stem cell transplantation is a life-saving therapy for hematological malignancies. The selection of a suitable donor has traditionally required a fully matched HLA. However, new immunosuppressive strategies have made it possible to recruit viable alternative donors, including haploidentical donors. The importance of KIR-driven NK cell alloreactivity in aHSCT outcomes remains unclear, and the literature shows discrepancies in the evaluation of its clinical benefit.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Scott M. Krummey, Alison J. Gareau
Summary: Advances in hematopoietic stem cell transplant have led to changes in donor selection approach, including the use of haploidentical donors or permissive HLA mismatches. However, this may increase the risk of donor-specific HLA antibodies, which can limit engraftment. Desensitization treatments can effectively reduce HLA antibodies and improve transplant outcomes. The consideration and management of HLA antibodies in donor selection are increasingly important in HSCT.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Friedrich Wittenbecher, Stella Lesch, Stefan Kolling, Igor-Wolfgang Blau, Lam Vuong, Franziska Borchert, Kamran Movasshagi, Carola Tietze-Buerger, Olaf Penack, Johann Ahn, Lars Bullinger, Marco Frentsch, Il-Kang Na
Summary: In this study, a comprehensive phenotypic analysis of 26 immune cell subsets was conducted using multicolor flow cytometry. The analysis was performed on only 100 μL of whole blood samples and provided extensive longitudinal data. The study found that the relative quantitative immune cell subset composition in recipients approached that of healthy donors after 180 days post alloHSCT. The proposed method could be a time efficient approach for broad immune assessment in future clinical studies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Kaito Harada
Summary: Donor lymphocyte infusion (DLI) is an allogenic immunotherapy used after allogeneic hematopoietic stem cell transplantation to prevent relapse or as maintenance therapy. DLI takes advantage of the graft-versus-tumor effect but can also lead to graft-versus-host disease. The response and efficacy of DLI depend on various factors, including patient, disease, and DLI factors.
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Shuang Fan, Meng-Zhu Shen, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Xiao-Su Zhao, Ya-Zhen Qin, Ying-Jun Chang, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Dong Mo
Summary: This study compared the efficacy of preemptive IFN-alpha therapy and DLI in t(8;21) AML patients following allo-HSCT and evaluated the appropriate method for patients with different levels of RUNX1-RUNX1T1 transcripts. The results showed that preemptive IFN-alpha therapy was more beneficial for patients with low-level and intermediate-level RUNX1-RUNX1T1, while clinical outcomes were comparable for patients with high-level RUNX1-RUNX1T1.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Christopher E. Dandoy, Stella M. Davies, Kwang Woo Ahn, Yizeng He, Anders E. Kolb, John Levine, Stephanie Bo-Subait, Hisham Abdel-Azim, Neel Bhatt, Joseph Chewing, Shahinaz Gadalla, Nicholas Gloude, Robert Hayashi, Nahal R. Lalefar, Jason Law, Margaret MacMillan, Tracy O'Brien, Timothy Prestidge, Akshay Sharma, Peter Shaw, Lena Winestone, Mary Eapen
Summary: This study compared transplant outcomes between myeloablative total body irradiation (TBI) containing and non-TBI regimens in children with de novo acute myeloid leukemia. The results showed that there was no difference in overall survival and leukemia-free survival between the two regimens, but TBI regimens had higher non-relapse mortality and lower relapse rates.
Review
Oncology
Stelios Kasikis, Aaron Etra, John E. Levine
Summary: GVHD, a common complication of HCT, is often treated with high-dose steroids, but treatment failure and steroid-refractory cases are common. Ruxolitinib is the first FDA-approved treatment for SR GVHD, with other new treatments currently under study.
Article
Hematology
Muna Qayed, Kwang Woo Ahn, Carrie L. Kitko, Mariam H. Johnson, Nirali N. Shah, Christopher Dvorak, Karin Mellgren, Brian D. Friend, Michael R. Verneris, Wing Leung, Jacek Toporski, John Levine, Joseph Chewning, Alan Wayne, Urvi Kapoor, Brandon Triplett, Kirk R. Schultz, Gregory A. Yanik, Mary Eapen
Summary: By analyzing a large cohort of AML and ALL patients, we developed and validated a DRI for children and adolescents that can be used to stratify patients based on disease risk and predict their survival rates.
Article
Biophysics
Sami B. Kanaan, Colleen Delaney, Filippo Milano, Andromachi Scaradavou, Koen van Besien, Judy Allen, Nathalie C. Lambert, Emma Cousin, Laurel A. Thur, Elena Kahn, Alexandra M. Forsyth, Oyku Sensoy, J. Lee Nelson
Summary: This study found that maternal cells from the cord blood graft can be tracked in recipients post-CBT, potentially reducing the risk of leukemia relapse, mortality, and treatment failure. Further investigation into cord blood maternal microchimerism is essential for sustained remission from leukemia following CBT.
BONE MARROW TRANSPLANTATION
(2021)
Article
Oncology
Benjamin Watkins, Muna Qayed, Courtney McCracken, Brandi Bratrude, Kayla Betz, Yvonne Suessmuth, Alison Yu, Shauna Sinclair, Scott Furlan, Steven Bosinger, Victor Tkachev, James Rhodes, Audrey Grizzle Tumlin, Alexandria Narayan, Kayla Cribbin, Scott Gillespie, Ted A. Gooley, Marcelo C. Pasquini, Kyle Hebert, Urvi Kapoor, Andre Rogatko, Mourad Tighiouart, Sungjin Kim, Catherine Bresee, Sung W. Choi, Jeffrey Davis, Christine Duncan, Roger Giller, Michael Grimley, Andrew C. Harris, David Jacobsohn, Nahal Lalefar, Maxim Norkin, Nosha Farhadfar, Michael A. Pulsipher, Shalini Shenoy, Aleksandra Petrovic, Kirk R. Schultz, Gregory A. Yanik, Edmund K. Waller, John E. Levine, James L. Ferrara, Bruce R. Blazar, Amelia Langston, John T. Horan, Leslie S. Kean
Summary: The study showed that adding abatacept to URD HCT was safe and effective in reducing AGVHD and improving SGFS. These results suggest that abatacept may have a significant positive impact on transplant outcomes related to AGVHD, particularly in HLA-mismatched HCT.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Ran Reshef, Wael Saber, Javier Bolanos-Meade, George Chen, Yi-Bin Chen, Vincent T. Ho, Doris M. Ponce, Ryotaro Nakamura, Michael J. Martens, John A. Hansen, John E. Levine
Summary: This study highlights the importance of accurate diagnosis and grading of acute GVHD, with findings suggesting that the incidence of GVHD may be overestimated at symptom onset. The study also demonstrates the need for a more structured framework for reporting and adjudication of GVHD in prospective trials.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Maureen M. O'Brien, Todd A. Alonzo, Todd M. Cooper, John E. Levine, Patrick A. Brown, Tamra Slone, Keith J. August, Bouchra Benettaib, Noha Biserna, Jennifer Poon, Meera Patturajan, Nianhang Chen, Mathew Simcock, Linda Zimmerman, E. Anders Kolb
Summary: Pediatric patients with relapsed/refractory AML treated with lenalidomide showed poor response rates, with one patient achieving complete response. Adverse events were common, indicating limited efficacy of lenalidomide in this population.
PEDIATRIC BLOOD & CANCER
(2021)
Article
Biophysics
Jeffrey R. Andolina, Yi-Cheng Wang, Lingyun Ji, David R. Freyer, John E. Levine, Michael A. Pulsipher, Alan S. Gamis, Richard Aplenc, Michael E. Roth, Lauren Harrison, Mitchell S. Cairo
Summary: Adolescent and young adult patients with acute leukemia have poorer outcomes compared to younger patients, and are more prone to developing acute and chronic GVHD following HLA matched sibling donor stem cell transplant.
BONE MARROW TRANSPLANTATION
(2022)
Letter
Biophysics
Sonia Elhadad, Amy Chadburn, Cynthia Magro, Koen Van Besien, Elisha D. O. Roberson, John P. Atkinson, Hunter Terry, June Greenberg, Whitney Reid, John Chapin, Dennis Copertino, Sahar Geramfard, Lizamarie Bachier Rodriguez, Nina Orfali, Usama Gerghis, Tsiporah Shore, Sebastian Mayer, Jasimuddin Ahamed, Jeffrey Laurence
BONE MARROW TRANSPLANTATION
(2022)
Letter
Oncology
Markus Plate, Jose Jessurun, Koen van Besien
LEUKEMIA & LYMPHOMA
(2023)
Article
Oncology
Carrie L. Kitko, Catherine M. Bollard, Mitchell S. Cairo, Joseph Chewning, Terry J. Fry, Michael A. Pulsipher, Shalini Shenoy, Donna A. Wall, John E. Levine
Summary: Since 2013, the Children's Oncology Group cellular therapy-based trials have advanced the field and set new standards of care for pediatric cancer. Key findings include improved survival with tandem autologous transplant for neuroblastoma and atypical teratoid/rhabdoid brain tumors, safer single umbilical cord blood donor compared to two donors, lack of survival improvement with killer immunoglobulin receptor (KIR) mismatched donors for pediatric acute myeloid leukemia, and the importance of minimal residual disease assessment for predicting relapse in acute lymphoblastic leukemia. Future plans include optimizing donor selection, using engineered cellular therapies, and developing better treatments for therapy toxicities.
PEDIATRIC BLOOD & CANCER
(2023)
Editorial Material
Hematology
John E. Levine
Article
Hematology
Santosh Putta, Bradford A. Young, John E. Levine, Ran Reshef, Ryotaro Nakamura, Christopher Strouse, Miguel -Angel Perales, Alan Howard, Polly Pine, Ju Shi, Peixin Zhang, Vincent T. Ho, Wael Saber
Summary: This study aimed to determine blood biomarkers that could identify high-risk patients for hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) shortly after hematopoietic cell transplantation (HCT). The study found that a combination of up to 5 protein biomarkers may provide a prognostic tool for identifying patients at risk for VOD/SOS.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Hannah-Lise T. Schofield, Vanessa A. Fabrizio, Suzanne Braniecki, Wendy Pelletier, Hesham Eissa, Beverly Murphy, Joseph Chewning, Karen D. Barton, Leanne M. Embry, John E. Levine, Kirk R. Schultz, Kristin M. Page
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Review
Hematology
Helen E. Heslop, Edward A. Stadtmauer, John E. Levine, Karen K. Ballen, Yi-Bin Chen, Amy E. DeZern, Mary Eapen, Mehdi Hamadani, Betty K. Hamilton, Parameswaran Hari, Richard J. Jones, Brent R. Logan, Leslie S. Kean, Eric S. Leifer, Frederick L. Locke, Richard T. Maziarz, Eneida R. Nemecek, Marcelo Pasquini, Rachel Phelan, Marcie L. Riches, Bronwen E. Shaw, Mark C. Walters, Amy Foley, Steven M. Devine, Mary M. Horowitz
Summary: This article summarizes the discussions and recommendations made by 11 committees at the 2021 BMT CTN State of the Science Symposium on hematopoietic stem cell transplant and cell therapy. The committees also considered clinical trial design and inclusion, diversity, and access as cross-cutting themes.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)